Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results
Apellis (Nasdaq: APLS) will host a conference call and webcast to discuss third quarter 2025 financial results on Thursday, October 30, 2025 at 8:30 a.m. ET.
Investors can pre-register to join by phone, and a live audio webcast plus slides will be available on the company’s Investors and Media "Events and Presentations" page. A replay of the webcast will be accessible for 90 days after the event.
Apellis describes itself as a global biopharmaceutical company focused on complement science with two C3-targeting medicines approved for four diseases; contact for investor inquiries is Eva Stroynowski at the company.
Apellis (Nasdaq: APLS) terrà una conference call e webcast per discutere i risultati finanziari del terzo trimestre 2025 giovedì 30 ottobre 2025 alle 8:30 ET.
Gli investitori possono preregistrarsi per partecipare telefonicamente, e sarà disponibile una presentazione audio in diretta con diapositive sulla pagina Investors and Media Events and Presentations dedicata agli investitori. Una replica del webcast sarà accessibile per 90 giorni dopo l'evento.
Apellis si descrive come una società biofarmaceutica globale focalizzata sulla scienza del complemento, con due farmaci mirati a C3 approvati per quattro malattie; il contatto per domande degli investitori è Eva Stroynowski presso l'azienda.
Apellis (Nasdaq: APLS) organizará una llamada de conferencia y webcast para discutir los resultados financieros del tercer trimestre de 2025 el jueves 30 de octubre de 2025 a las 8:30 a. m. ET.
Los inversores pueden pre-registrarse para unirse por teléfono, y habrá un webcast en directo con audio y diapositivas disponibles en la página de Investors and Media Events and Presentations de la compañía. Una reproducción del webcast estará disponible durante 90 días después del evento.
Apellis se describe a sí misma como una empresa global de biofarmacia centrada en la ciencia del complemento, con dos medicamentos dirigidos a C3 aprobados para cuatro enfermedades; para consultas de inversores está contactando Eva Stroynowski en la empresa.
Apellis (나스닥: APLS)는 컨퍼런스 콜 및 웨비스트를 주최하여 2025년 3분기 재무 실적을 2025년 10월 30일 목요일 오전 8:30 ET에 논의합니다.
투자자들은 전화로 참여하기 위해 미리 등록할 수 있으며, 라이브 오디오 웨비스트와 슬라이드가 회사의 Investors and Media 'Events and Presentations' 페이지에 제공됩니다. 웨비스트의 재방송은 이벤트 종료 후 90일간 이용 가능합니다.
Apellis는 스스로를 보완계(C3) 표적 약물을 두 가지 보유한 글로벌 바이오제약 회사로 설명하며, 네 가지 질병에 승인된 약물이 있습니다. 투자자 문의 담당자는 Eva Stroynowski 입니다.
Apellis (Nasdaq : APLS) organisera une conférence téléphonique et webcast pour discuter des résultats financiers du troisième trimestre 2025 le jeudi 30 octobre 2025 à 8 h 30 HE.
Les investisseurs peuvent s’inscrire préalablement pour participer par téléphone, et un webcast audio en direct avec des diapositives sera disponible sur la page Investors and Media Events and Presentations de l’entreprise. Une rediffusion du webcast sera accessible pendant 90 jours après l’événement.
Apellis se décrit comme une société biopharmaceutique mondiale axée sur la science du complément, avec deux médicaments ciblant C3 approuvés pour quatre maladies; le contact pour les demandes des investisseurs est Eva Stroynowski au sein de l’entreprise.
Apellis (Nasdaq: APLS) wird eine Telefonkonferenz und Webcast abhalten, um die Finanzergebnisse des dritten Quartals 2025 zu besprechen, am Donnerstag, 30. Oktober 2025 um 8:30 Uhr ET.
Investoren können sich vorab anmelden, um telefonisch teilzunehmen, und es wird einen Live-Audio-Webcast mit Folien auf der Seite des Unternehmens Investors and Media Events and Presentations verfügbar sein. Eine Wiedergabe des Webcasts wird 90 Tage nach der Veranstaltung zugänglich sein.
Apellis beschreibt sich selbst als globales Biopharma-Unternehmen, das sich auf die Komplementenforschung konzentriert, mit zwei auf C3 zielenden Medikamenten, die für vier Krankheiten zugelassen sind; der Ansprechpartner für Investorennachfragen ist Eva Stroynowski beim Unternehmen.
Apellis (ناسداك: APLS) ستستضيف اتصالًا هاتفيًا وبثًا حيًا عبر الويب لمناقشة نتائج الربع الثالث من عام 2025 في الخميس 30 أكتوبر 2025 الساعة 8:30 صباحًا بتوقيت شرق الولايات المتحدة.
يمكن للمستثمرين التسجيل مسبقًا للانضمام عبر الهاتف، وسيكون هناك بث صوتي مباشر مع شرائح متاحة على صفحة Investors and Media Events and Presentations الخاصة بالشركة. ستتوفر إعادة بث webcast لمدة 90 يومًا بعد الحدث.
تصف آبيليس نفسها بأنها شركة أدوية حيويّة عالمية تركز على علوم المكملات مع دوائين يستهدفان C3 ومُعَتَّمان لِأربعة أمراض؛ جهة الاتصال لاستفسارات المستثمرين هي إيفا ستروينوسكي في الشركة.
Apellis (纳斯达克股票代码：APLS) 将主持一个 电话会议和网络广播，以讨论2025年第三季度的财务业绩，时间为 2025年10月30日星期四美国东部时间上午8:30。
投资者可以提前登记通过电话参加，公司的投资者与媒体“事件与展示”页面将提供现场音频网络广播及幻灯片。网络广播的重播将于活动结束后提供 90天。
Apellis 自我描述为一家全球生物制药公司，专注于补体科学，拥有两种C3靶向药物，已获批用于四种疾病；投资者咨询联系人为 eva Stroynowski。
- None.
- None.
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 F, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2025 financial results on Thursday, October 30, 2025, at 8:30 a.m. ET.
To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on LinkedIn and X.
Investor Contact:
Eva Stroynowski
eva.stroynowski@apellis.com
617.938.6229
FAQ
When will Apellis (APLS) discuss third quarter 2025 results?
How can investors join the Apellis (APLS) Q3 2025 conference call?
Will the Apellis (APLS) Q3 2025 webcast be available after the event?
Where can I find the Apellis (APLS) event slides for the Q3 2025 call?
Who is the investor contact for Apellis (APLS) regarding the Q3 2025 call?
What will Apellis (APLS) cover during the October 30, 2025 call?
